Presentations

08:00

🎗Mapping the BK polyomavirus MHC class I immunopeptidome to advance antiviral immune target discovery in kidney transplants

Tirath Dwivedi (AU)

Bio Abstract

08:10

Unsupervised Machine Learning Reveals Early BKPyV DNAemia Trajectories That Improve the Prediction of Kidney Allograft Outcomes

Gang Huang (CN)

Bio Abstract

08:17

Breakthrough CMV DNAemia in solid organ recipients on primary valganciclovir prophylaxis

Sara Belga (CA)

Bio Abstract

08:24

Cytomegalovirus DNAemia clearance with maribavir in solid organ transplant recipients with symptomatic versus asymptomatic infection: a post hoc analysis of phase 2 and 3 trials

Deepali Kumar (CA)

Bio Abstract

08:31

When CMV donor/recipient risk is not one-size-fits-all: Demographic and socioeconomic modification of CMV-associated mortality after heart transplantation

Maheen Abidi (US)

Bio Abstract

08:38

Extended antiviral prophylaxis mitigates impact of cytomegalovirus infection in seronegative lung transplant recipients

Manushika Watagodakumbura (AU)

Bio Abstract

08:45

Early Initiation of Letermovir Prophylaxis Prevents Cytomegalovirus Infection After Liver Transplantation: A Prospective Single-Center Study

Katsunori Sakamoto (JP)

Bio Abstract

08:50

CMV specific cell mediated immunity profile in Indian kidney transplant recipients

Ramanand Sivaprasad (IN)

Bio Abstract

08:55

Utilization, Prevention, and Outcomes of Kidney Transplantation from HBsAg(+) Donors to HBsAg(-) Recipients: A Nationwide Survey of 74 Centers in Mainland China

Ying Su (CN)

Bio Abstract